BME100 f2015:Group16 8amL2

From OpenWetWare
Jump to navigationJump to search

Lab 2: Using Statistics

BME100 Group16 Lab2 Human.png
BME100 Group16 Lab2 Rat.png

Human Trials:
BME100 Group16 Lab2 HumanGraph.png

Rat Trials:
BME100 Group16 Lab2 RatGraph.png

ANOVA for humans:
BME100 Group16 Lab2 HumanANOVA.png

T-Test for humans:
BME100 Group16 Lab2 HumanT-Test.png

T-test for rats:
BME100 Group16 Lab2 RatT-Test.png

Based on the data we encountered it has become evident that the greater the dosage of LPS the greater the inflammotin in both the human study and the rat study. At 0mg of LPS the average inflammotin was 3.834. At 5mg of LPS the average was 8.932. At 10mg of LPS the average was 61.622 and at 15mg of LPS the average inflammotin was 657.941. In these human study results we can see the increase of one causing the increase of the other. The same relationship is shown in the rat study. As the value of the LPS dosage increases the inflammotin proteins in the body increase as well. Based on the p level at 95% confidence being less than the critical value this means that the known hypothesis will be rejected meaning there is a significant difference between each dosage and their corresponding inflammotin concentration.